Selected research
Industry Research
Varicella Virus Attenuated Live Vaccine Industry Research Report 2026
Market perspective
The global Varicella Virus Attenuated Live Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Varicella Virus Attenuated Live Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Varicella Virus Attenuated Live Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Varicella Virus Attenuated Live Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Varicella Virus Attenuated Live Vaccine include GSK, Changsheng, Sanofi, Merck, Biken, Shanghai Institute, Keygen, Green Cross and BCHT, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Varicella Virus Attenuated Live Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Varicella Virus Attenuated Live Vaccine Market by Company
GSK
Changsheng
Sanofi
Merck
Biken
Shanghai Institute
Keygen
Green Cross
BCHT
Varicella Virus Attenuated Live Vaccine Segment by Type
Child
Adult
Varicella Virus Attenuated Live Vaccine Segment by Application
Government Institution
Private Sector
Other
Varicella Virus Attenuated Live Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Varicella Virus Attenuated Live Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Varicella Virus Attenuated Live Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Varicella Virus Attenuated Live Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Varicella Virus Attenuated Live Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Varicella Virus Attenuated Live Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Varicella Virus Attenuated Live Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Child
- Adult
Applications
- Government Institution
- Private Sector
- Other
Companies covered
- GSK
- Changsheng
- Sanofi
- Merck
- Biken
- Shanghai Institute
- Keygen
- Green Cross
- BCHT
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Varicella Virus Attenuated Live Vaccine Market Size (2021-2032)
- 2.2.2 Global Varicella Virus Attenuated Live Vaccine Sales (2021-2032)
- 2.2.3 Global Varicella Virus Attenuated Live Vaccine Market Average Price (2021-2032)
- 2.3 Varicella Virus Attenuated Live Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Child
- 2.3.3 Adult
- 2.4 Varicella Virus Attenuated Live Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Government Institution
- 2.4.3 Private Sector
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Varicella Virus Attenuated Live Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Varicella Virus Attenuated Live Vaccine Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Varicella Virus Attenuated Live Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Varicella Virus Attenuated Live Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Varicella Virus Attenuated Live Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Varicella Virus Attenuated Live Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Varicella Virus Attenuated Live Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Varicella Virus Attenuated Live Vaccine, Established Date
- 3.9 Global Varicella Virus Attenuated Live Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 GSK
- 4.1.1 GSK Company Information
- 4.1.2 GSK Business Overview
- 4.1.3 GSK Varicella Virus Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GSK Varicella Virus Attenuated Live Vaccine Product Portfolio
- 4.1.5 GSK Recent Developments
- 4.2 Changsheng
- 4.2.1 Changsheng Company Information
- 4.2.2 Changsheng Business Overview
- 4.2.3 Changsheng Varicella Virus Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Changsheng Varicella Virus Attenuated Live Vaccine Product Portfolio
- 4.2.5 Changsheng Recent Developments
- 4.3 Sanofi
- 4.3.1 Sanofi Company Information
- 4.3.2 Sanofi Business Overview
- 4.3.3 Sanofi Varicella Virus Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sanofi Varicella Virus Attenuated Live Vaccine Product Portfolio
- 4.3.5 Sanofi Recent Developments
- 4.4 Merck
- 4.4.1 Merck Company Information
- 4.4.2 Merck Business Overview
- 4.4.3 Merck Varicella Virus Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Merck Varicella Virus Attenuated Live Vaccine Product Portfolio
- 4.4.5 Merck Recent Developments
- 4.5 Biken
- 4.5.1 Biken Company Information
- 4.5.2 Biken Business Overview
- 4.5.3 Biken Varicella Virus Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Biken Varicella Virus Attenuated Live Vaccine Product Portfolio
- 4.5.5 Biken Recent Developments
- 4.6 Shanghai Institute
- 4.6.1 Shanghai Institute Company Information
- 4.6.2 Shanghai Institute Business Overview
- 4.6.3 Shanghai Institute Varicella Virus Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Shanghai Institute Varicella Virus Attenuated Live Vaccine Product Portfolio
- 4.6.5 Shanghai Institute Recent Developments
- 4.7 Keygen
- 4.7.1 Keygen Company Information
- 4.7.2 Keygen Business Overview
- 4.7.3 Keygen Varicella Virus Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Keygen Varicella Virus Attenuated Live Vaccine Product Portfolio
- 4.7.5 Keygen Recent Developments
- 4.8 Green Cross
- 4.8.1 Green Cross Company Information
- 4.8.2 Green Cross Business Overview
- 4.8.3 Green Cross Varicella Virus Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Green Cross Varicella Virus Attenuated Live Vaccine Product Portfolio
- 4.8.5 Green Cross Recent Developments
- 4.9 BCHT
- 4.9.1 BCHT Company Information
- 4.9.2 BCHT Business Overview
- 4.9.3 BCHT Varicella Virus Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 BCHT Varicella Virus Attenuated Live Vaccine Product Portfolio
- 4.9.5 BCHT Recent Developments
5 Global Varicella Virus Attenuated Live Vaccine Market Scenario by Region
- 5.1 Global Varicella Virus Attenuated Live Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Varicella Virus Attenuated Live Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Varicella Virus Attenuated Live Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Varicella Virus Attenuated Live Vaccine Sales by Region: 2027-2032
- 5.3 Global Varicella Virus Attenuated Live Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Varicella Virus Attenuated Live Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Varicella Virus Attenuated Live Vaccine Revenue by Region: 2027-2032
- 5.4 North America Varicella Virus Attenuated Live Vaccine Market Facts & Figures by Country
- 5.4.1 North America Varicella Virus Attenuated Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Varicella Virus Attenuated Live Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Varicella Virus Attenuated Live Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Varicella Virus Attenuated Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Varicella Virus Attenuated Live Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Varicella Virus Attenuated Live Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Varicella Virus Attenuated Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Varicella Virus Attenuated Live Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Varicella Virus Attenuated Live Vaccine Market Facts & Figures by Country
- 5.7.1 South America Varicella Virus Attenuated Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Varicella Virus Attenuated Live Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Varicella Virus Attenuated Live Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Varicella Virus Attenuated Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Varicella Virus Attenuated Live Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Varicella Virus Attenuated Live Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Varicella Virus Attenuated Live Vaccine Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Varicella Virus Attenuated Live Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Varicella Virus Attenuated Live Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Varicella Virus Attenuated Live Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Varicella Virus Attenuated Live Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Varicella Virus Attenuated Live Vaccine Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Varicella Virus Attenuated Live Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Varicella Virus Attenuated Live Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Varicella Virus Attenuated Live Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Varicella Virus Attenuated Live Vaccine Value Chain Analysis
- 8.1.1 Varicella Virus Attenuated Live Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Varicella Virus Attenuated Live Vaccine Production Mode & Process
- 8.2 Varicella Virus Attenuated Live Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Varicella Virus Attenuated Live Vaccine Distributors
- 8.2.3 Varicella Virus Attenuated Live Vaccine Customers
9 Global Varicella Virus Attenuated Live Vaccine Analyzing Market Dynamics
- 9.1 Varicella Virus Attenuated Live Vaccine Industry Trends
- 9.2 Varicella Virus Attenuated Live Vaccine Industry Drivers
- 9.3 Varicella Virus Attenuated Live Vaccine Industry Opportunities and Challenges
- 9.4 Varicella Virus Attenuated Live Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst